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Abstract 
Objectives: The aim of this work was to determine the serum 
laminin level cutoff point for predicting liver ﬁ brosis highlighting 
its diagnostic value and determining the effect of treatment on 
serum laminin concentrations. 
Methods: Serum laminin concentrations in chronic hepatitis 
patients (n=62) and controls (n=20) were compared by ELISA and 
stages of ﬁbrosis were assessed according to the modiﬁ ed Knodell 
score system. 
Results: Mean serum laminin concentration in patients (91.9 
± 20.9 ng/ml) was greater than controls (46.2 ± 10.2 ng/ml; p 
<0.001). Serum concentrations of laminin in all stages of hepatic 
ﬁbrosis were signiﬁcantly higher than those of healthy controls (p 
<0.05). A cutoff point of 52ng laminin/ml of serum was obtained 
for the discrimination of various stages of liver ﬁ brosis showing 
a good sensitivity (96.8%) and speciﬁcity (80%). After 6 months 
of treatment, a gradual decrease in serum laminin concentrations 
were observed, however the level was still higher than that of the 
healthy group (p<0.05). 
Conclusions: Our ﬁndings suggest that the serum laminin 
concentration is a useful noninvasive marker of liver ﬁ brosis and 
shows a strong positive correlation with different stages of the 
disease. 
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Introduction 
Laminin was initially identiﬁed by Timpl and Martin in 1979, from a 
murine ﬁbrosarcoma (1). Laminin is one of the main glycoproteins 
of the basement membrane and participates in a series of such 
biological phenomena such as adhesion, migration, cellular 
differentiation and the maintenance of the cytoskeleton upon its 
binding to several components of the matrix, such as collagen type 
IV, heparin sulphate and entacin (2-7). 
In the liver, laminin is normally found around the vessels and biliary 
ducts, where basement membranes are identiﬁed. Little or only a 
slight reaction for antibodies against laminin can be observed in the 
hepatic sinusoids (8, 9). In this organ, glycoproteins are also involved 
in intracellular activities, such as the normal differentiation of the 
biliary ducts, expression of albumin messenger RNA in hepatocytes, 
and regeneration with normal lobular organization following 
partial hepatectomy (10-12). Laminin is thought to be synthesized 
by hepatocytes and sinusoidal cells (13). Among all cellular types 
in the sinusoids, special attention should be given to stellate cells 
or lipocytes, which produce the largest amount of serum laminin. 
With the development of hepatic cirrhosis, laminin and collagen 
deposition occurs both along the ﬁbers of septal ﬁ brosis and 
subendothelial sinusoids or Disse’s space. At the latter site, laminin 
deposition, together with collagen deposition, determine the 
formation of a true basement membrane along sinusoids. This 
phenomenon is called capillarization of Disse’s space (14).  
Increased concentrations of laminin were observed in the more 
advanced stages of ﬁbrosis in patients with hepatic disease (15­
19). Kropf et al have proposed laminin serum concentrations as 
a sensitive screening test for hepatic ﬁbrotic disease and portal 
hypertension (18, 19). 
An important component of the management of hepatic ﬁ brosis 
is the clinical assessment of disease severity. Liver histology is 
frequently considered the gold standard for establishing the 
severity of hepatic necro inﬂammation and ﬁbrosis. However, liver 
biopsy is an invasive procedure that may cause undesirable events, 
such as pain in 20% to 30% of cases, major complications in 0.5%, 
and even death. In addition, because of the complications derived 
from the procedure and frequent poor patient acceptance, the 
direct costs of such procedures are high (20). Thus, the ﬁ nding of 
surrogate markers of liver ﬁbrosis could be relevant to reduce the 
number of liver biopsies in patients with hepatitis. 
The ﬁrst aim of this study was to determine the serum laminin level 
cut off point to predict both presence and absence of ﬁ brosis. The 
second aim was to obtain a relationship between the diagnostic 
values of serum laminin concentrations for differentiation of 
various stages of hepatic ﬁbrosis in patients with chronic hepatitis. 
The ﬁnal aim was to determine serum laminin changes during 
treatment of these patients. 
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Materials and methods 
Study population 
62 patients (35 men and 27 women, mean age ± SD: 35.4 ± 11.3; 
range: 15-65 years) were enrolled in the study. Among these, 
35 patients had hepatitis B virus (HBV), 14 had hepatitis C virus 
(HCV), and 13 were autoimmune hepatitis (AIH). The subjects were 
selected from persons who were referred to the Gastroenterology 
Research Centres in Tabriz and Gonbad, Iran. Patients were 
included in the study if they were positive for serum hepatitis B 
surface antigen or C antibodies and had persistently elevated serum 
aminotransferase concentrations greater than 1.5 times the upper 
limit of the reference range for at least six months. All patients 
were diagnosed according to the International Autoimmune 
Hepatitis Group Report protocol (21). 
For assessment of liver ﬁbrosis scores all patients underwent liver 
biopsy as part of the normal diagnostic procedure and were sub-
classiﬁed according to the score for the histological activity index 
(HAI). Patients with a history of gastrointestinal bleeding and 
chronic liver disease (Wilson’s disease, hemochromatosis, a1pha 
1-antitrypsin deﬁciency, biliary disease, hepatocellular carcinoma), 
active intravenous drug abuse, and liver transplantation were 
excluded. 
Control sera for the determination of laminin were obtained from 
20 healthy individuals; 10 women and 10 men, 20-69 years old (mean 
± SD: 42 ± 14.7 years).These healthy persons had normal serum 
concentrations of aminotransferases and alkaline phosphatase 
(ALP) and had no history of gastrointestinal bleeding or chronic 
liver disease, smoking, alcohol intake, no family history of hepatitis 
or liver disease, and no active intravenous drug abuse, or liver 
transplantation. All patients gave written informed consent to use 
these data for scientiﬁc purposes and the study was approved by 
Tabriz University of Medical Sciences Ethical Committee. 
Blood sample collection and analysis 
Fasting venous blood (5ml) was collected on the day before the 
beginning of the treatment and three times at two monthly intervals, 
i.e. two, four and six months after the beginning of treatment. 
Serum was separated (2500 g for 5 minutes) within one hour of 
blood collection. Standard liver function tests (LFT), including 
aspartate aminotransferase (AST), alanine aminotransferase (ALT),
total and direct bilirubin, albumin (Alb), and hepatitis serology 
were performed on aliquots of each sample at entry and recorded. 
The rest of the serum samples were stored at – 20oC. Serum 
laminin concentrations were determined in one analytical batch. 
The controls were dealt with in the same manner, except that the 
control group provided blood only once at entry. Routine LFT were 
performed using commercially available kits (Ziestchem, Iran). 
Patients treatments were begun if they met the inclusion criteria 
and they were followed up for at least six months. Treatment of 
each patient was according to a standard protocol as follows. 
Hepatitis C patients were treated with Pegylated Interferon + 
Ribaverin or Interferon + Ribaverin. Hepatitis B patients were 
treated with Interferon or Adefovir and the AIH patients with 
Prednisolone and Imuran (22). 
Serum laminin concentrations were assayed using a laminin EIA 
Kit (Takara Bio, code number: MK107) on an ELISA reader (BDSL, 
Immunoscan, Switzerland, Lab System). The laminin EIA kit is 
a solid phase EIA based on a sandwich method that utilizes two 
mouse monoclonal anti–laminin antibodies to detect laminin by a 
two-step procedure. One of the monoclonal antibodies is bound to 
the microtitre plate to create the solid phase. Non-speciﬁ c binding 
is blocked using a blocking buffer. Samples and standards are then 
incubated in the microtitre plate wells. After washing the plate, 
the second anti-laminin monoclonal antibody that is labeled with 
peroxidase (POD) is added to the wells and incubated. During these 
steps, laminin is captured onto the solid support on one side and 
tagged on the other by POD-anti-laminin. The reaction between 
POD and substrate (H2O2 and tetremethybenzidine) results in 
color development with intensities proportional to the amount 
of laminin present in the samples and standards. The amount of 
laminin was determined by measuring the absorbances using an 
EIA plate reader. A standard curve of 5, 10, 20, 40, 80, 160 and 
320 ng/ml laminin was used to convert sample absorbances into ng 
laminin/ml serum. 
Histological assessment of liver damage 
All patients underwent a liver biopsy for assessing the presence 
and severity of liver disease. The biopsy fragments were ﬁ xed in 
a 10% formalin solution for 12 hours and embedded in parafﬁ n. 
Sections were stained with hematoxylin-eosin, Masson’s tri chrome 
and reticulin stain to establish the histological diagnosis and the 
extent of the liver lesions. 
Specimens were graded and staged according to the modiﬁ ed 
Knodell scoring system (23, 24). The grading system scores 0-18 and 
was based on sum of four indices: 
1. 	 Periportal or periseptal interface hepatitis (piecemeal necrosis, 
score 0-4) 
2. 	Conﬂuent necrosis (score 0-6) 
3. 	 Focal (spotty) lytic necrosis, apoptosis, and focal inﬂ ammation 
(score 0-4) 
3. 	Portal inﬂammation (score 0-4) 
The ﬁbrosis scores were determined as Stage 0 if there was no 
ﬁbrosis, Stage 1 if there was ﬁbrous expansion of some portal 
areas, with or without short ﬁbrous septa, Stage 2 if there was 
ﬁbrous expansion of most portal areas, with or without short 
ﬁbrous septa, Stage 3 if there was ﬁbrous expansion of most portal 
areas with occasional portal to portal (P-P) bridging, Stage 4 if 
there was ﬁbrous expansion of portal areas with marked bridging 
[portal to portal (P-P) as well as portal to central (P-C)], Stage 5 
if there was marked bridging (P-P and/or P-C) with occasional 
nodules (incomplete cirrhosis), and Stage 6 if there was probable 
or deﬁnite cirrhosis (23,24). 
Statistical analysis 
All statistical analyses were done by SPSS version 12.0 for Microsoft 
Windows (SPSS Inc.) and the data were considered statistically 
signiﬁcant at a two-sided p < 0.05. Numerical data were expressed 
as mean ± SD. According to the Gaussian distribution (1 sample 
Kolmogorov-Smirnov test), mean of serum laminin concentrations 
of patients and various chronic hepatitis stages, as well as the
control group, were compared using the Mann-Whitney U-test or 
Student's t test. Spearman's correlation coefﬁcients were calculated 
to assess the relationship between the histological degree of severe 
liver ﬁbrosis and the concentrations of serum laminin. 
To assess and compare the diagnostic accuracy of laminin for 
differentiating chronic hepatitis patients with severe liver 
ﬁbrosis from those without ﬁbrosis, we plotted ROC curves (25) 
and calculated the areas under the curves (AUC) for comparison. 
Receiver operating characteristic (ROC) curves were generated 
by plotting the relationship of the true positivity (sensitivity) 
and the false positivity (1 - speciﬁcity) at various cutoff points of 
the test. An AUC of 1.0 is characteristic of an ideal test, whereas 
0.5 indicates a test of no diagnostic value (26). The diagnostic 
sensitivity, speciﬁcity, positive predictive values (PPV) and negative 
predictive values (NPV) values were also calculated. 
Results 
Serological and biochemical proﬁles of the patients are summarized 
in Table 1. Hepatitis serology revealed that 56.4% of the patients 
were suffering from chronic hepatitis B, 22.5% from chronic 
hepatitis C and 20.9% from autoimmune hepatitis. Histological 
examination of liver for ﬁbrosis scoring revealed 35% of patients 
to be suffering from signiﬁ cant ﬁ brosis (stage ≥3). 
The mean serum laminin concentrations (ng/ml ± SD) in patients 
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Table 1. Serological and biochemical proﬁle of patients and control group. 
Variables Patients (n=62) Control group (n=20) 
Male/Female (No) 35 / 27 10 / 10 
Age in years (mean ± SD) 35.4 ± 11.3 42 ± 14.7 
ALT (mean ± SD) 
Reference range: < 38 IU/L 
132.7 ± 141.7 27.3 ± 6.4 
AST (mean ± SD) 
Reference range: < 42 IU/L 
97.0 ± 138.3 28.3 ± 6.5 
ALP (mean ± SD) 
Reference range: women 64-305 IU/L; men 80-306 IU/L 
376.4 ± 413.7 130.6 ± 38 
Total bilirubin (mean ± SD) 
Reference range: <20.5 µmol/L 
32.5 ± 58.1 -
Direct bilirubin Direct (mean ± SD) 
Reference range: < 6.8 µmol/L 
11.5 ± 23.1 -
Albumin (mean ± SD) 
Reference range: 35.0-52.0 g/L 
41.0 ± 6.0 -
Hemoglobin (mean ± SD) 
Reference range: women 12.0-16.0 g/L; men 14.0-18.0 g/L 
13.1 ± 2.6 -
Hematocrit (mean ± SD) 
Reference range: women 37.0-47.0%; men 40.0-54.0% 
41 ± 9.1 -
Platelets (mean ± SD) 
Reference range: 160,000-450,000 
220,511 ± 132,732 -
Smoking (No, %) 7 (11%) 0 (0%) 
Alcohol intake (No, %) 1 (1.6%) 0 (0%) 
Family history of hepatitis (No, %) 5 (8%) 0 (0%) 
Family history of chronic liver disease (No, %) 1 (1.6%) 0 (0%) 
History of drug abuse (No, %) 2 (3.2%) 0 (0%) 
Chronic hepatitis B (No, %) 35 (56.4%) 0 (0%) 
Chronic hepatitis C (No, %) 14 (22.5%) 0 (0%) 
Autoimmune hepatitis (No, %) 13 (20.9%) 0 (0%) 
Fibrosis Stage 0 (No, %) 10 (16.1%) 0 (0%) 
Fibrosis Stage 1 (No, %) 19 (30.6%) 0 (0%) 
Fibrosis Stage 2 (No, %) 11, 17.7% 0, 0% 
Fibrosis Stage 3 (No, %) 9, 14.5% 0, 0% 
Fibrosis Stage 4 (No, %) 8, 12.9% 0, 0% 
Fibrosis Stage 5 (No, %) 4, 6.4% 0, 0% 
Fibrosis Stage 6 (No, %) 1, 1.6% 0, 0% 
Table 2. Comparison of serum laminin concentrations (ng/ml, 
              stages of sampling vs. healthy controls. 
mean ± SD) of patients in various stages of liver ﬁbrosis and various 
Laminin 
concentrations 
Fibrosis Stage 0 Fibrosis Stage 1 Fibrosis Stage 2 Fibrosis Stage 3 Fibrosis Stage 4 Fibrosis Stage 5 
At entry 63.0 ± 12.1† 85.7 ± 6.3‡ 94.0 ± 10.2‡ 100.6 ± 8.6‡ 104.2 ± 20.2‡ 130.2 ± 13.7‡ 
2nd month 55.4 ± 8.5† 79.5 ± 6.6‡ 90.9 ± 12.0‡ 96.0 ± 7.0‡ 100.4 ± 18.4‡ 118.2 ± 19.0‡ 
4th month 49.2 ± 6.0* 75.3 ± 7.0‡ 85.7 ± 12.4‡ 90.0 ± 5.0‡ 93.0 ± 15.2‡ 111.7 ± 12.6‡ 
6th month 46.2 ± 4.5* 75.2 ± 6.0‡ 83.8 ± 11.1‡ 87.6 ± 5.9‡ 88.9 ± 13.0‡ 110.2 ± 9.5‡ 
Results are mean ± SD. Differences: *statistically not signiﬁcant; †p <0.05; ‡ p <0.001 
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with HBV, HCV and AIH were 92.0 ± 20.9 (range: 63-149), 92.8 ± 
24.2 (range: 43-128), 90.6 ± 18.4 (range: 69-128), respectively. 
However, the mean serum laminin concentrations (ng/ml ± SD) in 
healthy control subjects were statistically signiﬁcantly lower than 
the patients serum laminin concentrations (46.2 ± 10.2; p < 0.001, 
Figure 1). 
In Table 2, mean ± SD of serum laminin concentrations in various 
chronic hepatitis stages and various stages of sampling are presented. 
As shown in this table, differences in serum concentrations of 
laminin, almost in all stages of hepatic ﬁbrosis as compared with 
the healthy controls, were not statistically signiﬁcant (p <0.05). 
An exception was in 3rd and 4th samples of patients in Stage 0 
(p=0.313 and 0.985, respectively). Also in ﬁbrosis Stage 6, which was 
represented by only one patient, we could not compare this single 
patient with the control group (laminin serum concentration in this 
stage: 143 ng/ml). As the degree of liver ﬁbrosis stage increased, 
there was a gradual rise in basal serum laminin concentrations at 
entry (rS=0.788, p-value<0.001, Figure 2). 
After the beginning of treatment, a decrease in serum laminin 
concentrations was observed. We compared serum laminin 
concentrations of patients after six months of treatment with 
the basal laminin concentrations (at entry) of each ﬁ brosis 
stage. Although there was a gradual decrease in serum laminin 
concentrations of progressive ﬁbrosis stages (i.e. Stages 4 and 5), 
differences were not statistically signiﬁ cant (p <0.093 and <0.054, 
respectively). Conversely in early stages of ﬁbrosis (i.e. Stages 0-3) 
differences between the serum laminin concentrations at entry 
compared with the laminin concentrations after the beginning 
of treatment were statistically signiﬁcant (for Stages 0 and 1, p 
<0.001; and for Stages 2 and 3 , p <0.05). 
Table 3 shows the cutoff point, sensitivity, and speciﬁcity of serum 
laminin concentrations. In this table the ROC curve data, for 
patients before and after the treatment, are presented. Figure 
4 illustrates the ROC curve of serum laminin concentrations in 
patients (at entry) for differentiation of patients with liver ﬁ brosis 
vs. control group. 
Discussion 
Several serum markers have been developed to assess ﬁ brogenesis 
and investigations have been made to replace liver biopsy with 
non-invasive markers of liver ﬁbrosis, which have been assessed 
in many studies. However, questions remain regarding their 
sensitivity and signiﬁcance and whether changes in concentrations 
of these markers during the treatment protocol can be detected 
(27). In our study we have assessed serum laminin concentrations 
in patients with chronic hepatitis in an attempt to evaluate its 
predictive value for the risk of ﬁbrosis progression. In addition, we 
have investigated changes in serum laminin concentrations during 
the treatment protocol. 
As shown in Table 2, the mean serum laminin concentrations in 
patients with chronic liver disease were signiﬁcantly higher than 
those of healthy controls. These results are consistent with other 
reported studies (16, 28). As the stage of liver ﬁ brosis increases, there 
is a rise in serum laminin concentrations (Table 2) and patients in a 
higher ﬁbrosis stage show higher serum laminin concentrations. In 
addition, as is clear from Figure 2, the correlation of serum laminin 
concentrations with various histological stages of liver ﬁ brosis 
revealed a strong positive correlation (rS= 0.788). This indicates a 
positive relationship between serum laminin concentrations and 
the degree of liver ﬁbrosis, and the two variables are linearly 
related (p < 0.001). As shown in Table 2, differences in serum 
concentrations of laminin at various stages during the treatment 
protocol, compared to healthy controls, were statistically signiﬁ cant 
(p <0.05). It seems that during the treatment protocol there was 
a decrease in serum laminin concentrations. After six months of 
treatment, gradual decreases in serum laminin concentrations 
were observed. When we compared basal serum laminin 
concentrations in patients (at entry) with the concentrations of 
laminin after 6 months of treatment, we observed that the serum 
laminin concentrations did not differ statistically in stages  4 and 5 
of liver ﬁbrosis. Conversely, in the early stages of liver ﬁ brosis (0-3) 
the differences were statistically signiﬁcant (p <0.05). Therefore, it 
appears that treatment is more effective in  the early stages of liver 
ﬁbrosis, because only  in patients with a liver ﬁbrosis score of less 
than 4 a decrease in serum laminin concentrations occurred after 
treatment. An increase in the inﬂammation grade of liver damage 
led to a rise in serum laminin concentrations, and the correlation is 
statistically signiﬁcant (data not shown). 
As shown in Table 3, a cutoff point of 52 ng laminin/ml serum was 
obtained for discrimination of various stages of liver ﬁ brosis with 
a reasonably good sensitivity, speciﬁcity, PPV and NPV. The AUC of 
serum laminin ROC curve was found to be 0.974 indicating that 
serum laminin is a useful diagnostic index of liver ﬁbrosis. We also 
used this cutoff point (52 ng/ml) for creating the ROC curve after 
treatment. Again, the results showed a reasonably good AUC, 
sensitivity, speciﬁcity, PPV and NPV. We conclude that this cutoff 
point is also suitable for discrimination of our patients with ﬁ brosis 
during treatment. 
Our data are consistent with the work of other groups who 
reported that serum laminin concentrations increase in chronic liver 
disease (28-36). Schneider et al (16) and Castera et al (37) reported 
that laminin concentrations increase in early stages of chronic liver 
disease and the highest concentrations were in active cirrhosis and 
chronic active hepatitis. 
Several mechanisms are proposed for the elevation of serum 
laminin concentrations in chronic hepatitis patients. Besides the 
increased production of laminin in the liver, an additional effect 
due to a lack of degradation of this protein by liver endothelial 
cells should also be considered. As demonstrated by Smedsrod et al 
(38), apart from an increase in tissue deposition or turnover, there 
would be a decrease in the liver’s ability to degrade this protein. 
In a study of alcoholic liver disease patients, serum laminin P1-
peptide concentrations were higher on admission (alcohol intake 
period) and rapidly returned toward the normal range through 
alcohol abstinence (39). 
In our study we observed that after the beginning of treatment 
a gradual decrease occurred in serum laminin concentrations. 
Possibly treatment of liver ﬁbrosis causes the liver endothelial cells 
to regenerate and new endothelial cells degrade this glycoprotein.
Further studies are needed to gain a complete understanding of 
laminin metabolism. 
In conclusion, the ﬁndings of our study suggest that serum laminin 
is a useful non-invasive marker of liver ﬁbrosis. There was a strong 
positive correlation between serum laminin concentrations and the 
degree of liver ﬁbrosis and inﬂammation (all stages and grades). 
Serum laminin concentrations may also be used for the follow-up of 
liver ﬁbrosis in patients with chronic liver disease as well as for the 
assessment of liver ﬁbrosis where liver biopsy is contraindicated. 
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Table 3. ROC curve of laminin serum level for discrimination o
before and after treatment. 
f patients with liver ﬁbrosis vs. control group (laminin cutoff point =52 ng/ml)
Stages of 
sampling 
AUC 
(95% CI) 
P Sensitivity Speciﬁ city PPV NPV 
Before treatment 
0.974 
(0.945 -1.004) 
<0.001 96.8% 80% 93.7% 88.8% 
After treatment 
0.926 
(0.837-0.980) 
<0.001 83.9% 80% 92.8% 61.5% 
AUC: area under the curve. 95% CI: 95% conﬁdence interval. PPV: positive predictive value. NPV: negative predictive value. 
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Figure 1. Box plot for serum laminin
concentrations (ng/ml) in patients
with hepatitis B virus (HBV), hepatitis
C virus (HCV), autoimmune hepatitis
(AIH) and control groups, at entry. 
Figure 2. Correlation between serum
laminin concentrations (at entry)
and stages of ﬁbrosis in liver biopsies
(rS=0.788, p < 0.001). 
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